Insmed, Inc. $INSM Shares Bought by Swiss National Bank

Swiss National Bank increased its position in Insmed, Inc. (NASDAQ:INSM) by 5.5% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 347,400 shares of the biopharmaceutical company’s stock after acquiring an additional 18,100 shares during the period. Swiss National Bank owned approximately 0.16% of Insmed worth $34,962,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in INSM. Chung Wu Investment Group LLC acquired a new position in shares of Insmed in the 2nd quarter valued at $173,000. Caxton Associates LLP purchased a new position in Insmed in the first quarter valued at about $441,000. Assenagon Asset Management S.A. raised its holdings in Insmed by 84.5% in the second quarter. Assenagon Asset Management S.A. now owns 73,404 shares of the biopharmaceutical company’s stock valued at $7,387,000 after acquiring an additional 33,626 shares in the last quarter. Public Employees Retirement System of Ohio bought a new stake in Insmed in the second quarter valued at about $5,578,000. Finally, Intech Investment Management LLC raised its holdings in shares of Insmed by 43.2% during the first quarter. Intech Investment Management LLC now owns 101,979 shares of the biopharmaceutical company’s stock worth $7,780,000 after purchasing an additional 30,752 shares during the period.

Analyst Ratings Changes

Several brokerages recently weighed in on INSM. UBS Group lifted their price objective on shares of Insmed from $194.00 to $223.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Bank of America boosted their target price on Insmed from $142.00 to $187.00 and gave the stock a “buy” rating in a research report on Monday, October 27th. Stifel Nicolaus raised their price objective on shares of Insmed from $121.00 to $145.00 and gave the stock a “buy” rating in a research note on Thursday, August 14th. Jefferies Financial Group lifted their price objective on Insmed from $129.00 to $148.00 and gave the company a “buy” rating in a research report on Wednesday, August 13th. Finally, Cantor Fitzgerald began coverage on Insmed in a report on Tuesday, October 28th. They issued an “overweight” rating and a $192.00 target price for the company. Nineteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $175.53.

Insmed Stock Performance

Insmed stock opened at $206.93 on Tuesday. The company’s 50-day moving average is $169.02 and its two-hundred day moving average is $126.58. The company has a market cap of $44.13 billion, a PE ratio of -36.24 and a beta of 1.05. Insmed, Inc. has a 1 year low of $60.40 and a 1 year high of $208.72. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The firm had revenue of $142.34 million during the quarter, compared to analyst estimates of $114.33 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business’s revenue was up 52.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.27) earnings per share. Insmed has set its FY 2025 guidance at EPS. Equities analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current year.

Insider Buying and Selling

In other Insmed news, Director Elizabeth M. Anderson sold 10,000 shares of the stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $195.87, for a total transaction of $1,958,700.00. Following the transaction, the director owned 63,729 shares in the company, valued at $12,482,599.23. This represents a 13.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Michael Alexander Smith sold 27,130 shares of the stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $183.78, for a total value of $4,985,951.40. Following the sale, the insider directly owned 54,902 shares in the company, valued at $10,089,889.56. This represents a 33.07% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 252,922 shares of company stock worth $43,533,383. Corporate insiders own 3.00% of the company’s stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.